Researchers are testing psilocybin for its potential to treat major depression in people without cancer, following a study that examined its effectiveness in cancer patients. Funding for research on psychedelics will allow for the necessary data production to bring the power of psychedelics to treat mental health disorders.
Psilocybin is being studied as a potential treatment option for various disorders, including anxiety and depression in people with Alzheimer's disease, emotional and behavioral symptoms of post-treatment Lyme disease syndrome, and major depression in people without cancer.
The John Hopkins Center for Psychedelic and Consciousness Research will conduct studies on various aspects of consciousness and psychedelics, including the therapeutic use of psilocybin for addiction and depression, and the effects of microdosing on creativity. A partnership with the John Hopkins Eating Disorders Program is also planned
The philanthropic model for large impact scientific funding of uncrowded areas with clear progress paths is discussed, with Catherine McCormick's work on the development of oral contraceptives as an example of such an approach.